Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III MelanomaAlexander M.M. Eggermont, Caroline Robert, Georgina V. Long et al.|NEJM Evidence|2022Cited by 152
Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trialAlexander M.M. Eggermont, Caroline Robert, Michal Kiciński et al.|European Journal of Cancer|2024Cited by 84